Betapace
NDC Package 70515-105-10
Package Information
Betapace is /Betapace AF is contraindicated in patients with:•Sinus bradycardia, sick sinus syndrome, second and third degree AV block, unless a functioning pacemaker is present•Congenital or acquired long QT syndromes•Cardiogenic shock or decompensated heart failure•Serum potassium <4 mEq/L•Bronchial asthma or related bronchospastic conditions•Hypersensitivity to sotalol For the treatment of AFIB/AFL, Betapace/Betapace AF is also contraindicated in patients with:•Baseline QT interval >450 msec. Marketed by Covis Pharma Us, Inc, this product is identified by NDC 70515-105 and is authorized under FDA application NDA019865.
Identification & Billing
- RxCUI: 1922720 - sotalol HCl AF 120 MG Oral Tablet
- RxCUI: 1922720 - Atrial Fibrillation sotalol hydrochloride 120 MG Oral Tablet
- RxCUI: 1922720 - sotalol hydrochloride AF 120 MG Oral Tablet
- RxCUI: 1922721 - Betapace AF 120 MG Oral Tablet
- RxCUI: 1922721 - Atrial Fibrillation sotalol hydrochloride 120 MG Oral Tablet [Betapace]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70515 - Covis Pharma Us, Inc
- 70515-105 - Betapace
- 70515-105-10 - 100 TABLET in 1 BOTTLE
- 70515-105 - Betapace
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70515-105-10 identifies a specific commercial package of 100 tablet in 1 bottle of Betapace, labeled by Covis Pharma Us, Inc. This product is billed for "EA" each discreet unit and contains an estimated amount of 100 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Covis Pharma Us, Inc on September 01, 2016. The current certification is valid through December 31, 2024.
How is this Covis Pharma Us, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70515010510. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.